Business article - February 20, 2016
A new era for Finnish life science
The Finnish health sector is getting a boost, creating a vital life science industry, where the field of digital health especially is growing at a rapid pace. No countries were spared when the economic crisis hit the entire world back in 2008. Finland took a big hit, and so did its life science sector. But […]
Business article - January 17, 2016
Denmark: a Life Science Standout
Industry-leaders get where they are by capitalizing on their strengths, whether that is an educated workforce, innovative thinkers, strong public-private partnerships or efficient government. With all these assets plus more, it is no surprise that Denmark has emerged as a world leader in the life sciences and health care. Thanks to world-class research facilities and […]
Business article - December 31, 2015
Denmark: best for business
Forbes Magazine ranks Denmark no. 1 in their global league table “Best Countries for Business”. Just recently, the World Bank ranked Denmark first in Europe in their Doing Business Report, and the Danish Minister for Foreign Affairs, Kristian Jensen, hopes that the recurring international recognition of the Danish business climate will attract more foreign investors:“Creating […]
Business article - December 9, 2015
Q&A with Barbro C. Ehnbom
Barbro C Ehnbom was awarded “Årest Läkemedelsprofil” or “Life Science Profile of the Year” in October this year. Ingrid Lund asked her five questions about life science today and in the future. How can Sweden and the US have the most effective exchange within life science in the future? “Sweden is good at innovation and […]
Business article - August 15, 2015
Life science opportunities in Poland
With the largest economy in central Europe, Poland is attracting a lot of interest from the Nordic life science industry. The country’s pharmaceutical, biotechnology, clinical trial and medical technology sectors all are expected to keep growing for the next several years. “Poland is a huge market of 38 million people with healthcare expenditures of 24 […]
Business article - June 2, 2015
Orphan Drugs Spur M&A Interest
Thanks to the potential for higher prices, limited competition and favorable regulations, orphan drugs continue to be popular to manufacture and also attractive to buy, and Moody’s predicts they will continue to generate merger and acquistion activity. Nearly half of recent acquisitons involved orphan drugs, or medications that treat serious conditions that affect fewer than […]
